MacroGenics Inc (NASDAQ:MGNX) SVP Eric Blasius Risser sold 3,000 shares of the firm’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $18.38, for a total transaction of $55,140.00. Following the transaction, the senior vice president now directly owns 33,806 shares of the company’s stock, valued at $621,354.28. The sale was disclosed in a document filed with the SEC, which is available through this link.
Eric Blasius Risser also recently made the following trade(s):
- On Wednesday, May 22nd, Eric Blasius Risser sold 4,000 shares of MacroGenics stock. The stock was sold at an average price of $18.54, for a total transaction of $74,160.00.
MGNX stock traded up $0.23 on Thursday, reaching $18.66. 33,830 shares of the company traded hands, compared to its average volume of 931,225. MacroGenics Inc has a one year low of $9.87 and a one year high of $32.32. The company has a quick ratio of 6.47, a current ratio of 6.47 and a debt-to-equity ratio of 0.08. The firm has a market cap of $914.62 million, a PE ratio of -4.42 and a beta of 2.90.
MacroGenics (NASDAQ:MGNX) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.99) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.95) by ($0.04). The business had revenue of $9.66 million during the quarter, compared to the consensus estimate of $11.46 million. MacroGenics had a negative return on equity of 57.65% and a negative net margin of 256.47%. On average, research analysts expect that MacroGenics Inc will post -3.7 earnings per share for the current fiscal year.
MGNX has been the topic of several recent research reports. HC Wainwright set a $39.00 price objective on shares of MacroGenics and gave the stock a “buy” rating in a research note on Wednesday, February 20th. Nomura upped their target price on MacroGenics from $41.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, February 7th. SunTrust Banks increased their price objective on MacroGenics to $40.00 and gave the company a “buy” rating in a research report on Thursday, February 7th. Citigroup upgraded MacroGenics from a “sell” rating to a “buy” rating and increased their price objective for the company from $10.00 to $39.00 in a research report on Thursday, February 7th. Finally, Cowen restated a “buy” rating on shares of MacroGenics in a research report on Thursday, May 2nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $32.07.
Several institutional investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company lifted its position in shares of MacroGenics by 3.7% in the first quarter. The Manufacturers Life Insurance Company now owns 25,971 shares of the biopharmaceutical company’s stock valued at $467,000 after acquiring an additional 929 shares in the last quarter. Legal & General Group Plc lifted its position in shares of MacroGenics by 20.4% in the fourth quarter. Legal & General Group Plc now owns 7,432 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 1,261 shares in the last quarter. Northern Trust Corp lifted its position in shares of MacroGenics by 0.3% in the fourth quarter. Northern Trust Corp now owns 524,500 shares of the biopharmaceutical company’s stock worth $6,661,000 after buying an additional 1,644 shares in the last quarter. Stifel Financial Corp lifted its position in shares of MacroGenics by 14.8% in the fourth quarter. Stifel Financial Corp now owns 18,034 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 2,327 shares in the last quarter. Finally, Marshall Wace North America L.P. purchased a new stake in shares of MacroGenics in the first quarter worth about $59,000. 87.02% of the stock is owned by institutional investors and hedge funds.
MacroGenics Company Profile
MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers.
Featured Article: Blockchain
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.